Macrogenics (MGNX) EBITDA Margin (2012 - 2026)
Macrogenics (MGNX) posted quarterly EBITDA Margin of 160.96% for Q1 2026, up 16215.0% year-over-year from N/an in Q1 2025, and down 448.55% quarter-over-quarter from 29.34% in Q4 2025.
Macrogenics (MGNX) EBITDA Margin (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported EBITDA Margin for 15 consecutive years, with 160.96% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 16215.0% year-over-year to 160.96%; the TTM figure through Mar 2026 stood at 40.53% (up 1640.0% YoY), while the FY2025 annual figure was 48.72%, up 2501.0% from the prior year.
- EBITDA Margin slipped to 160.96% in Q1 2026 per MGNX's latest filing, from 29.34% in the prior quarter.
- Across five years, EBITDA Margin topped out at 48.95% in Q3 2024 and bottomed at 600.29% in Q1 2022.
- Historically, EBITDA Margin has averaged 233.59% across 5 years, with a median of 160.96% in 2026.
- On a YoY basis, EBITDA Margin climbed as much as 44342 bps in 2023 and fell as far as 47678 bps in 2023.
- Macrogenics' EBITDA Margin stood at 16.39% in 2022, then slumped by 2908 bps to 460.39% in 2023, then jumped by 71 bps to 132.09% in 2024, then surged by 78 bps to 29.34% in 2025, then slumped by 449 bps to 160.96% in 2026.
- Business Quant data shows MGNX's EBITDA Margin at 160.96% in Q1 2026, 29.34% in Q4 2025, and 25.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -160.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -160.96% |
| Dec 31, 2025 | -29.34% |
| Sep 30, 2025 | 25.59% |
| Jun 30, 2025 | -165.27% |
| Mar 31, 2025 | -323.10% |
| Dec 31, 2024 | -132.09% |
| Sep 30, 2024 | 48.95% |
| Jun 30, 2024 | -538.86% |
| Mar 31, 2024 | -590.40% |
| Dec 31, 2023 | -460.39% |
| Sep 30, 2023 | -341.46% |
| Jun 30, 2023 | -342.28% |
| Mar 31, 2023 | -156.87% |
| Dec 31, 2022 | 16.39% |
| Sep 30, 2022 | -59.80% |
| Jun 30, 2022 | -160.76% |
| Mar 31, 2022 | -600.29% |
| Dec 31, 2021 | -411.65% |
| Sep 30, 2021 | -338.32% |
| Jun 30, 2021 | -130.96% |